However, the utility of CRISPR-Cas9 is subject to its specificity, as this system may result in a significant level of non-specific editing at other unplanned genomic loci. 1, 2 These unwanted additional mutations, called off-target mutations, could be silent or may have pathogenic consequences, and significant concerns remain over the detrimental effects of these mutations. The specificity of this genome editing system is mediated by a predesigned guide RNA (gRNA) of 100 nucleotides, which binds to the Cas9 nuclease and leads the way to the 20-nt protospacer, a specific region of the target DNA. Numerous studies have recently shown that recognition by gRNA and cleavage by Cas9 may lead to mutagenesis of unintended genomic sites, and it is still unclear whether and how frequently this off-targeting occurs. Given its wide applicability from discovery science to the development of therapeutics, there is a demanding need to increase CRISPR-Cas9 specificity by lowering the probability of targeting any other undesirable sites in the genome. Predicting how the gRNA will bind to sequences in the genome, in silico tools have been developed to assess the efficiency and specificity of CRISPR-Cas9 before moving to in vivo studies. The accuracy of these tools relies on the ability to gauge how each gRNA binds to DNA and how Cas9 performs its cut. Over the past few years, several unbiased in vitro and cell-based genomewide screening assays have been developed to bypass this limitation and to identify unforeseen off-target mutations. However, these assays cannot be directly applied to in vivo identification of off-target mutation sites.
In a recent report, 3 Dr P. Akcakaya, Dr J. Keith Joung and colleagues applied a system to effectively identify genome-wide off-target mutations from CRISPR-Cas9 genome editing and showed in mice that a carefully designed gRNA does not produce any detectable off-target mutations. They described an original two-step approach named 'verification of in vivo targets' (VIVO) to firstly identify potential off-target sites, and then to confirm if these sites have been altered after in vivo genome editing. The first part of the research strategy, called CIRCLE-seq, was performed in vitro and has been recently described in Nature Methods.
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CIRCLE-seq spots off-target sites cleaved in vitro by Cas9 by selecting only the cleaved genomic DNA. In brief, genomic DNA is sheared and circularized by intramolecular ligation. After introduction of a Cas9-gRNA complex, the circular DNA containing the Cas9 cleavage site is cleaved and thus linearized. The cleaved ends are then amplified and high-throughput sequenced to predict the sites at which the gRNA will cause off-target effects in vivo. In the second step, Akcakaya et al. assessed these identified sites by CIRCLE-seq for indel mutations by targeted amplicon sequencing, performed with genomic DNA isolated from the livers of nuclease-treated mice. To test VIVO, the authors designed a promiscuous gRNA (gP-Cas9) targeting the mouse Pcsk9 gene, predicted by in silico tools to cause numerous off-target mutations, and delivered it to mouse liver in vivo by infecting a cohort of wild-type mice (C57/BL6N) and knock-in mice (single copy of a human PCSK9 open reading frame knocked into the Rosa26 locus) with an adenoviral vector. Using CIRCLE-seq they identified many off-target cleavage sites in vitro, while 42% (19/45) of these identified sites (with frequencies as low as 0.13%) showed evidence of indels in vivo. Next, the authors used two other gRNAs (gM and gMH) predicted to be highly specific to their target sites in mouse Pcsk9. gM and gMH previously had been validated as being active in mouse liver, 5, 6 and gMH also targeted a site in the human PCSK9 gene integrated in the knock-in mice. The CIRCLE-seq analysis detected many fewer off-target sites with the two more specific gRNAs compared with gP, and after performing target amplicon sequencing the authors were unable to observe any offtarget indels in vivo at any of the identified sites. The use of this new and elegant approach named VIVO in CRISPRCas9 genome editing enables us to identify off-target mutations in vivo and to develop safer strategies to specifically target desired sites in the genome. The development of more powerful in silico tools remains essential in the design of the most specific gRNA displaying the minimum number of closely matched genomic sites (with three or fewer mismatches). VIVO is an elegant method to experimentally define off-target sites before pursuing the use of CRISPR-Cas9 in animal models and clinical cohorts of patients. Therefore, VIVO strongly encourages and supports the further development of therapeutic strategies using in vivo gene editing, which could be used for instance for the prevention or treatment of cardiovascular diseases. 7 The strategies used could vary from inducing beneficial mutations protecting against cardiac events to correction of pre-existing pathological mutations. 8, 9 Overcoming the challenges of applying CRISPR-Cas9-mediated genome editing in vivo will give rise to new precision medicine approaches. This is particularly important because we have already entered the genomic and big data era in health care.
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